CLINICAL TRIALS PROFILE FOR LIPOFEN
✉ Email this page to a colleague
All Clinical Trials for LIPOFEN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | Leducq Foundation | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | National Heart, Lung, and Blood Institute (NHLBI) | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | National Institutes of Health (NIH) | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT01752842 ↗ | Lipid Biomarkers for Diabetic Heart Disease | Completed | Washington University School of Medicine | N/A | 2013-03-01 | This study will test whether lowering the delivery of excess fats to the heart in persons with type-2 diabetes mellitus improves heart muscle function. The investigators will also test whether specific lipid molecular species in plasma can serve as biomarkers for diabetic heart disease. |
| NCT02158273 ↗ | Medication Development in Alcoholism: Investigating PPAR Agonists | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 2014-05-01 | The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo. |
| NCT02158273 ↗ | Medication Development in Alcoholism: Investigating PPAR Agonists | Completed | The Scripps Research Institute | Phase 2 | 2014-05-01 | The primary hypotheses under test are that alcohol dependent subjects treated with fenofibrate will report decreased craving for alcohol following cue-exposure in the laboratory and report less drinking post treatment relative to placebo. |
| NCT06191133 ↗ | Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma | Not yet recruiting | Lindsay Ferguson, MD | Phase 1 | 2024-08-01 | Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of HPV-positive tumors in a way that stops the growth of tumors. The purpose of this study is to understand how Fenofibrate can be used to treat HPV-positive cervical cancers and cervical dysplasia. Researchers will examine collected tissue samples and investigate various genes and proteins to see whether Fenofibrate has an effect on HPV-positive cervical cancers and cervical dysplasia. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for LIPOFEN
Condition Name
Clinical Trial Locations for LIPOFEN
Trials by Country
Clinical Trial Progress for LIPOFEN
Clinical Trial Phase
Clinical Trial Sponsors for LIPOFEN
Sponsor Name
